The Claim
In older adults with coronary artery disease participating in cardiac rehabilitation, 12 weeks of daily low-dose rapamycin (0.5–1.0 mg) did not improve frailty, despite observed changes in certain senescence biomarkers, suggesting that molecular-level effects may not result in functional clinical benefits in this population.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Older adults with heart disease who took a low dose of a drug called rapamycin every day for 3 months didn’t get less frail, even though the drug changed some aging-related markers in their bodies.
See the scientific wording
In older adults with coronary artery disease undergoing cardiac rehabilitation, 12 weeks of daily low-dose rapamycin (0.5–1.0 mg) did not lead to improvement in frailty, despite observed changes in some senescence biomarkers, indicating that molecular changes may not translate to functional benefits in this population.
What the research says
1 studyThe study gave older heart patients a low dose of rapamycin for 12 weeks and saw changes in aging-related markers, but their physical frailty didn't get better. This matches the claim that the drug didn't help with frailty even though it changed some biological signs.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.